Skip to main content

Advertisement

Springer Nature Link
Log in

Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M

  • Original Article
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Abstract

The protein kinase D (PKD) family of proteins are important regulators of tumor growth, development, and progression. CRT0066101, an inhibitor of PKD, has antitumor activity in multiple types of carcinomas. However, the effect and mechanism of CRT0066101 in bladder cancer are not understood. In the present study, we show that CRT0066101 suppressed the proliferation and migration of four bladder cancer cell lines in vitro. We also demonstrate that CRT0066101 blocked tumor growth in a mouse flank xenograft model of bladder cancer. To further assess the role of PKD in bladder carcinoma, we examined the three PKD isoforms and found that PKD2 was highly expressed in eight bladder cancer cell lines and in urothelial carcinoma tissues from the TCGA database, and that short hairpin RNA (shRNA)-mediated knockdown of PKD2 dramatically reduced bladder cancer growth and invasion in vitro and in vivo, suggesting that the effect of the compound in bladder cancer is mediated through inhibition of PKD2. This notion was corroborated by demonstrating that the levels of phospho-PKD2 were markedly decreased in CRT0066101-treated bladder tumor explants. Furthermore, our cell cycle analysis by flow cytometry revealed that CRT0066101 treatment or PKD2 silencing arrested bladder cancer cells at the G2/M phase, the arrest being accompanied by decreases in the levels of cyclin B1, CDK1 and phospho-CDK1 (Thr161) and increases in the levels of p27Kip1 and phospho-CDK1 (Thr14/Tyr15). Moreover, CRT0066101 downregulated the expression of Cdc25C, which dephosphorylates/activates CDK1, but enhanced the activity of the checkpoint kinase Chk1, which inhibits CDK1 by phosphorylating/inactivating Cdc25C. Finally, CRT0066101 was found to elevate the levels of Myt1, Wee1, phospho-Cdc25C (Ser216), Gadd45α, and 14-3-3 proteins, all of which reduce the CDK1-cyclin B1 complex activity. These novel findings suggest that CRT0066101 suppresses bladder cancer growth by inhibiting PKD2 through induction of G2/M cell cycle arrest, leading to the blockade of cell cycle progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

    Article  PubMed  Google Scholar 

  2. Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev 25:16–27

    Article  Google Scholar 

  3. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y (2017) Bladder cancer. Nat Rev Dis Prim 3:17022

    Article  PubMed  Google Scholar 

  4. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239–249

    Article  CAS  PubMed  Google Scholar 

  5. Fletcher A, Choudhury A, Alam N (2011) Metastatic bladder cancer: a review of current management. ISRN Urol 2011:545241

    PubMed  PubMed Central  Google Scholar 

  6. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866

    Article  CAS  PubMed  Google Scholar 

  7. Dovedi SJ, Davies BR (2009) Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 28:355–367

    Article  CAS  PubMed  Google Scholar 

  8. Bellmunt J, Petrylak DP (2012) New therapeutic challenges in advanced bladder cancer. Semin Oncol 39:598–607

    Article  CAS  PubMed  Google Scholar 

  9. Weintraub MD, Li QQ, Agarwal PK (2014) Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (review). Mol Clin Oncol 2:656–660

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mohammed AA, El-Tanni H, El-Khatib HM, Mirza AA, Mirza AA, Alturaifi TH (2016) Urinary bladder cancer: biomarkers and target therapy, new era for more attention. Oncol Rev 10:320

    Article  PubMed  PubMed Central  Google Scholar 

  11. Alpsoy A, Gunduz U (2015) Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells. Tumour Biol 36:4417–4426

    Article  CAS  PubMed  Google Scholar 

  12. Zhu Y, Cheng Y, Guo Y, Chen J, Chen F, Luo R, Li A (2016) Protein kinase D2 contributes to TNF-α-induced epithelial mesenchymal transition and invasion via the PI3 K/GSK-3β/β-catenin pathway in hepatocellular carcinoma. Oncotarget 7:5327–5341

    PubMed  Google Scholar 

  13. Wong C, Jin ZG (2005) Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J Biol Chem 280:33262–33269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ha CH, Wang W, Jhun BS, Wong C, Hausser A, Pfizenmaier K, McKinsey TA, Olson EN, Jin ZG (2008) Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem 283:14590–14599

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dequiedt F, Van Lint J, Lecomte E, Van Duppen V, Seufferlein T, Vandenheede JR, Wattiez R, Kettmann R (2005) Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J Exp Med 201:793–804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bastea LI, Doppler H, Balogun B, Storz P (2012) Protein kinase D1 maintains the epithelial phenotype by inducing a DNA-bound, inactive SNAI1 transcriptional repressor complex. PLoS One 7:e30459

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zheng H, Shen M, Zha YL, Li W, Wei Y, Blanco MA, Ren G, Zhou T, Storz P, Wang HY, Kang Y (2014) PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell 26:358–373

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Baron CL, Malhotra V (2002) Role of diacylglycerol in PKD recruitment to the TGN and protein transport to the plasma membrane. Science 295:325–328

    Article  CAS  PubMed  Google Scholar 

  19. Hausser A, Storz P, Martens S, Link G, Toker A, Pfizenmaier K (2005) Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIβ at the Golgi complex. Nat Cell Biol 7:880–886

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Waldron RT, Rozengurt E (2000) Oxidative stress induces protein kinase D activation in intact cells. Involvement of Src and dependence on protein kinase C. J Biol Chem 275:17114–17121

    Article  CAS  PubMed  Google Scholar 

  21. Zugaza JL, Sinnett-Smith J, Van Lint J, Rozengurt E (1996) Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J 15:6220–6230

    PubMed  PubMed Central  Google Scholar 

  22. Hao Q, McKenzie R, Gan H, Tang H (2013) Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells. Anticancer Res 33:393–399

    CAS  PubMed  Google Scholar 

  23. Wei N, Chu E, Wipf P, Schmitz JC (2014) Protein kinase d as a potential chemotherapeutic target for colorectal cancer. Mol Cancer Ther 13:1130–1141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Liou GY, Storz P (2015) Protein kinase D enzymes: novel kinase targets in pancreatic cancer. Expert Rev Gastroenterol Hepatol 9:1143–1146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S (2010) A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 9:1136–1146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Durand N, Borges S, Storz P (2016) Protein kinase D enzymes as regulators of EMT and cancer cell invasion. J Clin Med 5:20

    Article  PubMed Central  Google Scholar 

  27. Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P (2015) Effective targeting of estrogen receptor-negative breast cancers with the protein kinase D inhibitor CRT0066101. Mol Cancer Ther 14:1306–1316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wei N, Chu E, Wu SY, Wipf P, Schmitz JC (2015) The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells. Oncotarget 6:4745–4756

    PubMed  Google Scholar 

  29. Verbon EH, Post JA, Boonstra J (2012) The influence of reactive oxygen species on cell cycle progression in mammalian cells. Gene 511:1–6

    Article  CAS  PubMed  Google Scholar 

  30. Lu Z, Hunter T (2010) Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 9:2342–2352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. McDonald ER 3rd, El-Deiry WS (2000) Cell cycle control as a basis for cancer drug development (review). Int J Oncol 16:871–886

    CAS  PubMed  Google Scholar 

  32. Lacy ER, Wang Y, Post J, Nourse A, Webb W, Mapelli M, Musacchio A, Siuzdak G, Kriwacki RW (2005) Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division. J Mol Biol 349:764–773

    Article  CAS  PubMed  Google Scholar 

  33. Hu X, Moscinski LC (2011) Cdc2: a monopotent or pluripotent CDK? Cell Prolif 44:205–211

    Article  CAS  PubMed  Google Scholar 

  34. O’Connell MJ, Walworth NC, Carr AM (2000) The G2-phase DNA-damage checkpoint. Trends Cell Biol 10:296–303

    Article  PubMed  Google Scholar 

  35. Brezak MC, Quaranta M, Mondesert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B (2004) A novel synthetic inhibitor of CDC25 phosphatases: bN82002. Cancer Res 64:3320–3325

    Article  CAS  PubMed  Google Scholar 

  36. Damia G, Broggini M (2004) Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle 3:46–50

    Article  CAS  PubMed  Google Scholar 

  37. Zhang Y, Hunter T (2014) Roles of Chk1 in cell biology and cancer therapy. Int J Cancer 134:1013–1023

    Article  CAS  PubMed  Google Scholar 

  38. Perdiguero E, Nebreda AR (2004) Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle 3:733–737

    Article  CAS  PubMed  Google Scholar 

  39. Mueller PR, Coleman TR, Kumagai A, Dunphy WG (1995) Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270:86–90

    Article  CAS  PubMed  Google Scholar 

  40. Ruiz EJ, Vilar M, Nebreda AR (2010) A two-step inactivation mechanism of Myt1 ensures CDK1/cyclin B activation and meiosis I entry. Curr Biol 20:717–723

    Article  CAS  PubMed  Google Scholar 

  41. Den Haese GJ, Walworth N, Carr AM, Gould KL (1995) The Wee1 protein kinase regulates T14 phosphorylation of fission yeast Cdc2. Mol Biol Cell 6:371–385

    Article  Google Scholar 

  42. Watanabe N, Broome M, Hunter T (1995) Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 14:1878–1891

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Parker LL, Sylvestre PJ, Byrnes MJ 3rd, Liu F, Piwnica-Worms H (1995) Identification of a 95-kDa WEE1-like tyrosine kinase in HeLa cells. Proc Natl Acad Sci USA 92:9638–9642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3:513–519

    CAS  PubMed  Google Scholar 

  45. Heller JD, Kuo J, Wu TC, Kast WM, Huang RC (2001) Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res 61:5499–5504

    CAS  PubMed  Google Scholar 

  46. Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK, Zhong Y, Reed E (2013) β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer Res 33:1421–1428

    CAS  PubMed  Google Scholar 

  47. Rotem A, Janzer A, Izar B, Ji Z, Doench JG, Garraway LA, Struhl K (2015) Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc Natl Acad Sci USA 112:5708–5713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–322

    Article  Google Scholar 

  49. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47

    Article  PubMed  PubMed Central  Google Scholar 

  50. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040–4048

    Article  CAS  PubMed  Google Scholar 

  51. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778–789

    Article  CAS  PubMed  Google Scholar 

  52. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11:4044–4055

    Article  CAS  PubMed  Google Scholar 

  53. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O’Connor PM, Fornace AJ Jr, Harris CC (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96:3706–3711

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Jiang K, Pereira E, Maxfield M, Russell B, Goudelock DM, Sanchez Y (2003) Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345. J Biol Chem 278:25207–25217

    Article  CAS  PubMed  Google Scholar 

  55. Wang Y, Jacobs C, Hook KE, Duan H, Booher RN, Sun Y (2000) Binding of 14-3-3β to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. Cell Growth Differ 11:211–219

    CAS  PubMed  Google Scholar 

  56. Rothblum-Oviatt CJ, Ryan CE, Piwnica-Worms H (2001) 14-3-3 Binding regulates catalytic activity of human Wee1 kinase. Cell Growth Differ 12:581–589

    CAS  PubMed  Google Scholar 

  57. Eastman A (2004) Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 91:223–231

    Article  CAS  PubMed  Google Scholar 

  58. Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677

    Article  CAS  PubMed  Google Scholar 

  59. Dynlacht BD (1997) Regulation of transcription by proteins that control the cell cycle. Nature 389:149–152

    Article  CAS  PubMed  Google Scholar 

  60. Choi YH, Lee WH, Park KY, Zhang L (2000) p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91:164–173

    Article  CAS  PubMed  Google Scholar 

  61. Lopez-Girona A, Furnari B, Mondesert O, Russell P (1999) Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397:172–175

    Article  CAS  PubMed  Google Scholar 

  62. Furnari B, Rhind N, Russell P (1997) Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277:1495–1497

    Article  CAS  PubMed  Google Scholar 

  63. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497–1501

    Article  CAS  PubMed  Google Scholar 

  64. Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace AJ Jr (1999) Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 18:2892–2900

    Article  CAS  PubMed  Google Scholar 

  65. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA (2002) GADD45b and GADD45g are cdc2/cyclin B1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. J Cell Physiol 192:327–338

    Article  CAS  PubMed  Google Scholar 

  66. Lee J, Kumagai A, Dunphy WG (2001) Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell 12:551–563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Moore JD, Yang J, Truant R, Kornbluth S (1999) Nuclear import of Cdk/cyclin complexes: identification of distinct mechanisms for import of Cdk2/cyclin E and Cdc2/cyclin B1. J Cell Biol 144:213–224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Takizawa CG, Weis K, Morgan DO (1999) Ran-independent nuclear import of cyclin B1-Cdc2 by importin β. Proc Natl Acad Sci USA 96:7938–7943

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B (1997) 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3–11

    Article  CAS  PubMed  Google Scholar 

  70. Guweidhi A, Kleeff J, Giese N, El Fitori J, Ketterer K, Giese T, Buchler MW, Korc M, Friess H (2004) Enhanced expression of 14-3-3σ in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 25:1575–1585

    Article  CAS  PubMed  Google Scholar 

  71. Courtois S, Caron de Fromentel C, Hainaut P (2004) p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 23:631–638

    Article  CAS  PubMed  Google Scholar 

  72. Draetta G, Eckstein J (1997) Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta 1332:M53–M63

    CAS  PubMed  Google Scholar 

  73. Izumi T, Maller JL (1993) Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell 4:1337–1350

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Bernhart E, Damm S, Wintersperger A, DeVaney T, Zimmer A, Raynham T, Ireson C, Sattler W (2013) Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro. Exp Cell Res 319:2037–2048

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Zou Z, Zeng F, Xu W, Wang C, Ke Z, Wang QJ, Deng F (2012) PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA. J Cell Sci 125:4800–4811

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Visconti R, Della Monica R, Grieco D (2016) Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. J Exp Clin Cancer Res 35:153

    Article  PubMed  PubMed Central  Google Scholar 

  77. Li QQ, Hao JJ, Zhang Z, Hsu I, Liu Y, Tao Z, Lewi K, Metwalli AR, Agarwal PK (2016) Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: a proteomic approach. Int J Oncol 48:2591–2607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Li QQ, Hao JJ, Zhang Z, Krane LS, Hammerich KH, Sanford T, Trepel JB, Neckers L, Agarwal PK (2017) Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Sci Rep 7:201

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported by the Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Author information

Author notes

  1. Quentin Li and Iawen Hsu contributed equally to this work.

Authors and Affiliations

  1. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

    Qingdi Quentin Li, Iawen Hsu, Thomas Sanford, Reema Railkar, Navin Balaji, Carole Sourbier, Cathy Vocke & Piyush K. Agarwal

  2. Wake Forest University School of Medicine, Winston Salem, NC, 27106, USA

    K. C. Balaji

Authors
  1. Qingdi Quentin Li
    View author publications

    Search author on:PubMed Google Scholar

  2. Iawen Hsu
    View author publications

    Search author on:PubMed Google Scholar

  3. Thomas Sanford
    View author publications

    Search author on:PubMed Google Scholar

  4. Reema Railkar
    View author publications

    Search author on:PubMed Google Scholar

  5. Navin Balaji
    View author publications

    Search author on:PubMed Google Scholar

  6. Carole Sourbier
    View author publications

    Search author on:PubMed Google Scholar

  7. Cathy Vocke
    View author publications

    Search author on:PubMed Google Scholar

  8. K. C. Balaji
    View author publications

    Search author on:PubMed Google Scholar

  9. Piyush K. Agarwal
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Qingdi Quentin Li or Piyush K. Agarwal.

Ethics declarations

Conflict of interest

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Q.Q., Hsu, I., Sanford, T. et al. Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. Cell. Mol. Life Sci. 75, 939–963 (2018). https://doi.org/10.1007/s00018-017-2681-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-017-2681-z

Keywords